12.5 LCI Pill - peach round, 8mm
Pill with imprint 12.5 LCI is Peach, Round and has been identified as Amphetamine and Dextroamphetamine 12.5 mg. It is supplied by Lannett Company, Inc.
Amphetamine/dextroamphetamine is used in the treatment of ADHD; Narcolepsy and belongs to the drug class CNS stimulants. Risk cannot be ruled out during pregnancy. Amphetamine/dextroamphetamine 12.5 mg is classified as a Schedule 2 controlled substance under the Controlled Substance Act (CSA).
Images for 12.5 LCI
Amphetamine and Dextroamphetamine
- Imprint
- 12.5 LCI
- Strength
- 12.5 mg
- Color
- Peach
- Size
- 8.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- CNS stimulants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- 2 - High potential for abuse
- Labeler / Supplier
- Lannett Company, Inc.
- National Drug Code (NDC)
- 00527-0763
Related images for "12.5 LCI"
More about amphetamine / dextroamphetamine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,142)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: CNS stimulants
- En español
Patient resources
- Amphetamine and dextroamphetamine drug information
- Dextroamphetamine and amphetamine (Advanced Reading)
- Dextroamphetamine and Amphetamine Tablets
- Dextroamphetamine and Amphetamine Extended-Release Capsules (Adderall XR)
- Dextroamphetamine and Amphetamine Extended-Release Capsules (Mydayis)
Other brands
Adderall, Adderall XR, Mydayis
Professional resources
- Amphetamine monograph
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate (FDA)
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate ER Capsules (FDA)
Other brands
Adderall, Adderall XR, Mydayis
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
